MEDIOS

Fact Sheet

Contact:
ir@medios.group
www.medios.group

Company Profile

Medios is a European Pharma Services group with two operating segments, Specialty Pharma Supply and Compounding, and operations in Germany, the Netherlands, Belgium and Spain. Working closely with pharmacies, specialist medical practices and pharmaceutical companies, Medios combines pharmaceutical expertise, manufacturing capabilities and smart services to enable reliable and efficient access to innovative and individualised therapies. Medios helps ensure reliable access to the therapies needed by patients living with complex and chronic conditions, including cancer, autoimmune, neurological and metabolic diseases.

Executive Board



Thomas Meier, CEO



Stefan Bauerreis, CFO



Christoph Prusseit, CBO[1] Germany
(till 31.12)



Constantijn van Rietschoten, CBO[1] International

PHARMACEUTICAL SUPPLY

- Highly focused on Specialty Pharma drugs
- 1,000 products available

PATIENT-SPECIFIC THERAPIES


- Strongly positioned in patient-specific medication
- 5 GMP Laboratories (>400,000 preparations/year)

INTERNATIONAL BUSINESS


- Leading full-service compounding services platform

Oncology | **Neurology** | **Autoimmune Diseases** | **Ophthalmology** | **Infectious Diseases** | **Hemophilia**


Revenue by Segments – 2025




EBITDA pre[2] by Segments – 2025



Consolidated Revenue in €m



Consolidated EBITDA pre[2] in €m



[1] CBO = Chief Business Officer, [2] adjusted for extraordinary expenses (EBITDA pre); [3]CAGR = Compound Annual Growth Rate

Fact Sheet

Contact:
ir@medios.group
www.medios.group

Key Figures

in €m	9M 2026 (IFRS)	9M 2025 (IFRS)	Change
Revenue	1,663.0	1,530.0	*+6.7 %*
EBITDA pre*	66.7	70.4	*-5.2 %*
Margin in %	*4.1*	*4.6*	*-0.5pp*

*adjusted for extraordinary expenses

Basic Information


Share Capital / No. of Shares	€25,505,723 / 25,505,723
Share Class	No-par Value Bearer Shares
ISIN / WKN / Ticker	DE000A1MMCC8 / A1MMCC / ILM1
Index	SDAX
Paying Agent	BankM AG
Stock Exchange / Places of Trading	Regulated Market Frankfurt (Prime Standard) Open Market Stuttgart and Duesseldorf Tradegate

Analysts: Deutsche Bank | Berenberg Bank | Metzler Capital Markets | Montega | MPCM / Warburg Research

Shareholder Structure

All figures according to voting rights notifications of the notifying parties

60.3%
Free float[1]
- 6.4% Janus Henderson
- 6.1% Axxion
- 3.9% Treasury Shares[2]
- 2.99% SEB Investment
- 2.4% Paladin Asset Management




19.7 %
Martin Hesse[3]
inkl. Zurechnung der BMSH GmbH

20.0 %
Luxempart Invest S.á.r.l.

[1] Free Float as defined by Deutsche Börse Group [2] Treasury shares from the share buy-back offer do not carry voting or dividend rights (treasury shares as of Nov 9, 2026: 986,362 shares) [3] Incl. attribution of BMSH GmbH

Medios Share Price Development vs. SDAX



SDAX rebased to Medios closing share price on 4 November 2025